↓ Skip to main content

MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2014
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy
Published in
Journal for Immunotherapy of Cancer, September 2014
DOI 10.1186/s40425-014-0032-2
Pubmed ID
Authors

Maxwell Janosky, Rachel L Sabado, Crystal Cruz, Isabelita Vengco, Farah Hasan, Arthur Winer, Linda Moy, Sylvia Adams

Abstract

Studies suggest that conventional cancer therapies given after immunotherapy (IT) can boost antitumor immunity and possibly improve response rates and progression-free survival. We report two cases of metastatic breast cancer with durable complete responses (CRs) after sequential IT and endocrine therapy. Immune analyses of these long-term disease-free breast cancer patients previously treated with imiquimod (IMQ) suggest in-situ vaccination is achieved by topical application of the TLR-7 agonist directly onto tumors. Furthermore, IT-induced antigen-specific T cells were expanded by subsequent endocrine therapy and correlated with response, persisting > 2 years. Our findings therefore suggest that the induction/boosting of polyfunctional tumor antigen-specific T in response to sequential immune endocrine therapy and detected directly ex-vivo can serve as a peripheral blood biomarker for true clinical benefit.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 21%
Student > Bachelor 2 14%
Researcher 2 14%
Professor 1 7%
Professor > Associate Professor 1 7%
Other 1 7%
Unknown 4 29%
Readers by discipline Count As %
Medicine and Dentistry 4 29%
Agricultural and Biological Sciences 3 21%
Immunology and Microbiology 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Unknown 5 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2015.
All research outputs
#22,853,823
of 25,481,734 outputs
Outputs from Journal for Immunotherapy of Cancer
#3,258
of 3,442 outputs
Outputs of similar age
#210,590
of 246,503 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#13
of 13 outputs
Altmetric has tracked 25,481,734 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,442 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.